Strides Pharma Science Ltd. (STAR) fundamentals
Strides Pharma Science Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as STAR (ISIN INE939A01011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Strides Pharma Science Ltd. does
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Valuation and market data
| Last close | ₹1029.10 |
|---|---|
| Market capitalisation | ₹9,798 crore |
| Enterprise value | ₹10,492 crore |
| P/E (TTM) | 17.05 |
| Price to book | 3.11 |
| Price to sales (TTM) | 1.13 |
| Book value per share | ₹330.76 |
| Dividend yield | 48.59% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 02 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹5,009 crore | ₹669 crore | ₹575 crore | 60.34 |
| Mar 2025 | ₹4,624 crore | ₹487 crore | ₹409 crore | 390.55 |
| Mar 2024 | ₹3,930 crore | ₹-115 crore | ₹-144 crore | -7.76 |
| Mar 2023 | ₹3,779 crore | ₹-286 crore | ₹-231 crore | -22.49 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 29.0% |
|---|---|
| Foreign institutions (FII) | 28.0% |
| Mutual funds | 10.3% |
| Other domestic institutions | 5.2% |
| Retail and others | 27.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.